

## BerGenBio

### Efficacy endpoint met in Phase II AML study

2 April 2019

- In the Phase II trial in AML with bemcentinib in combination with low-dose cytarabine (LDAC), the pre-specified efficacy endpoint has been met; at least three patients out of the first 14 patients (21%) were required to achieve a clinical response.
- Of the 15 patients enrolled, 10 patients were evaluable for response to date with 4 newly diagnosed and 6 relapsed/refractory (R/R) patients. Among the newly diagnosed patients, there was one complete remission (CR) and one CR with incomplete haematologic recovery (CRi) observed; and among the R/R there was one CR observed. So, overall 3 of the 10 evaluable patients (CR/CRi rate of 30%) have achieved a clinical response.
- The responses had an early onset (after 1-2 cycles), were durable, and deepened over time.
- The combination treatment was well tolerated with no overlapping or new toxicities observed; all responders were over the age of 75 and included patients with poor risk prognosis.
- More detailed results from the trial, including biomarker data, will be presented at upcoming medical conferences.
- BerGenBio expects to start a late-stage bemcentinib monotherapy trial in R/R AML patients in H219.

Price	NOK25.00
Market Cap	NOK1,371m
Primary exchange	Oslo
Sector	Healthcare
Company Code	BGBIO
Corporate client	Yes

#### Company description:

BerGenBio is a clinical-stage, drug development company based in Bergen, Norway and Oxford, UK. It is developing innovative anti-cancer therapies that act on the promising Ax1 signalling pathway. The lead oncology compound, bemcentinib, is in a number of Phase II trials.

**Trinity Delta view:** BerGenBio has already reported promising bemcentinib monotherapy data from this Phase II trial (CR/CRi/CRp rate of 22% from all 27 patients treated and 43% from the 14 patients with low levels of the sAx1 biomarker, see [Outlook](#) note from January 2019). This data suggests that bemcentinib can also increase the activity of LDAC, the current standard of care for elderly AML patients and that has an ORR of only c18%.

Our valuation of BerGenBio is NOK3,143m (\$370m) or NOK57.45/share and data from the Phase II study in NSCLC with pembrolizumab due in the coming months could be important share price catalysts. The overall survival data from the first stage of the Phase II study in NSCLC with pembrolizumab and initial results from the trial's second stage are due in Q219.

#### Analysts

##### Mick Cooper PhD

mcooper@trinitydelta.org  
+44 (0) 20 3637 5042

##### Lala Gregorek

lgregorek@trinitydelta.org  
+44 (0) 20 3637 5043

**Mick Cooper PhD CFA**

[mcooper@trinitydelta.org](mailto:mcooper@trinitydelta.org)

+44 20 3637 5042

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)

+44 20 3637 5043

**Franco Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)

+44 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2019 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)